Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD

被引:0
|
作者
Helen L. Reeves
Marco Y. W. Zaki
Christopher P. Day
机构
[1] Northern Institute for Cancer Research,Institute of Cellular Medicine
[2] Newcastle University,undefined
来源
关键词
Hepatocellular carcinoma; Obesity; Type 2 diabetes; Nonalcoholic fatty liver disease; PNPLA3; Macrophage; Inflammation; Autophagy;
D O I
暂无
中图分类号
学科分类号
摘要
Hepatocellular carcinoma (HCC) is the second commonest cause of cancer death worldwide. Rather than falling as a result of prevention and treatments for viral hepatitis, an increase is evident in developed nations consequent to the rising prevalence of obesity and type 2 diabetes mellitus (T2DM)—the two major risk factors for nonalcoholic fatty liver disease (NAFLD). The majority of patients with HCC complicating these conditions present with advanced disease as the tools for surveillance are inadequate, and the “at-risk” population is not well characterized. This review will summarize the epidemiological evidence linking obesity, T2DM, and NAFLD with HCC, what is known about the pathogenic mechanisms involved, as well as their relevance for clinicians managing patients at risk. There will also be an overview of the “unmet needs” surrounding this topic, with suggestions for the direction translational research should take in order to prevent progression of NAFLD to HCC, to improve early detection of HCC in those with NAFLD, as well as to improve outcomes for those affected.
引用
收藏
页码:1234 / 1245
页数:11
相关论文
共 50 条
  • [41] Editorial: screening for hepatocellular carcinoma in NAFLD-towards abbreviated MRI alternative in patients with obesity?
    Lebosse, Fanny
    Caussy, Cyrielle
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (09) : 1210 - 1211
  • [42] Why Does NAFLD Predict Type 2 Diabetes?
    Guido Lattuada
    Francesca Ragogna
    Gianluca Perseghin
    Current Diabetes Reports, 2011, 11 : 167 - 172
  • [43] Association between Type 2 Diabetes Genetic Susceptibility Loci and Hepatocellular Carcinoma in Patients with Type 2 Diabetes as Determined by Fibroscan
    Korenaga, Masaaki
    Ueyama, Misuzu
    Nishida, Nao
    Korenaga, Keiko
    Kawaguchi, Takumi
    Hyogo, Hideyuki
    Aikata, Hiroshi
    Kumagai, Erina
    Aoki, Yoshihiko
    Sugiyama, Masaya
    Imamura, Masatoshi
    Murata, Kazumoto
    Kanto, Tatsuya
    Masaki, Naohiko
    Mizokami, Masashi
    HEPATOLOGY, 2014, 60 : 623A - 623A
  • [44] Correlation of Macrovascular Complications with NAFLD in Type 2 Diabetes
    Agrawal, Navneet
    Jatav, O. P.
    Gupta, Manish
    DIABETES, 2009, 58 : A549 - A550
  • [45] Why Does NAFLD Predict Type 2 Diabetes?
    Lattuada, Guido
    Ragogna, Francesca
    Perseghin, Gianluca
    CURRENT DIABETES REPORTS, 2011, 11 (03) : 167 - 172
  • [46] Liraglutide Improves NAFLD in Patients with Type 2 Diabetes
    Basu, Debasis
    Chaudhuri, Soumyabrata Roy
    Deka, Nilakshi
    DIABETES, 2020, 69
  • [47] NAFLD, Insulin Resistance, and Diabetes Mellitus Type 2
    Marusic, Marinko
    Paic, Matej
    Knobloch, Mia
    Liberati Prso, Ana-Marija
    CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 2021
  • [48] Risk and Prognosis of Hepatocellular Carcinoma in Mexican Americans with Type 2 Diabetes Mellitus
    Hatia, Rikita I.
    Hwang, Lu-Yu
    Li, Ruosha
    Troisi, Catherine
    Jalal, Prasun K.
    Amos, Christopher I.
    Gomez, Henry F.
    Chun, Yun Shin
    Rashid, Asif
    Kaseb, Ahmed O.
    Scheet, Paul A.
    Hassan, Manal M.
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2025, 12 : 93 - 106
  • [49] Relationships Among Type 2 Diabetes Mellitus, Antidiabetic Therapy and Hepatocellular Carcinoma
    Perciaccante, Antonio
    Balbi, Massimiliano
    Casarin, Pietro
    Zanette, Giorgio
    Donadon, Valter
    GASTROENTEROLOGY, 2009, 136 (05) : A859 - A860
  • [50] Association of liver cirrhosis severity with type 2 diabetes mellitus in hepatocellular carcinoma
    Makol, Ankita
    Kanthaje, Shruthi
    Dhiman, Radha K.
    Kalra, Naveen
    Chawla, Yogesh K.
    Chakraborti, Anuradha
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2018, 243 (04) : 323 - 326